Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Allogene Therapeutics, Inc.

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
From Allogene Therapeutics, Inc.
Via Globe NewsWire
Tickers ALLO
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.